Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

MYELODYSPLASTIC SYNDROME

Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mutational landscape and clonal architecture of CREBBP and EP300 genes and their functional and structural domains.
Fig. 2: CREBBP/EP300 RNA expression analysis and its effect on survival outcomes.

Data availability

The results presented in this study were in part generated through TCGA (dbGaP Study Accession: phs000178; Principal Investigator: JPM). Requests for additional information should be made to the corresponding author.

References

  1. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.

    Article  CAS  Google Scholar 

  2. Qian M, Zhang H, Kham SK, Liu S, Jiang C, Zhao X, et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 2017;27:185–95.

    Article  CAS  Google Scholar 

  3. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–95.

    Article  CAS  Google Scholar 

  4. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch’ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 1998;93:361–72.

    Article  CAS  Google Scholar 

  5. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA. 2002;99:14789–94.

    Article  CAS  Google Scholar 

  6. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood. 1997;90:4699–704.

    Article  CAS  Google Scholar 

  7. Ohnishi H, Taki T, Yoshino H, Takita J, Ida K, Ishii M, et al. A complex t(1;22;11)(q44;q13;q23) translocation causing MLL-p300 fusion gene in therapy-related acute myeloid leukemia. Eur J Haematol. 2008;81:475–80.

    Article  CAS  Google Scholar 

  8. Duhoux FP, De Wilde S, Ameye G, Bahloula K, Medves S, Légé G, et al. Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes. Leuk Res. 2011;35:e18–20.

    Article  CAS  Google Scholar 

  9. Raisner R, Kharbanda S, Jin L, Jeng E, Chan E, Merchant M, et al. Enhancer activity requires CBP/P300 bromodomain-dependent histone H3K27 acetylation. Cell Rep. 2018;24:1722–9.

    Article  CAS  Google Scholar 

  10. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24:1799–804.

    Article  CAS  Google Scholar 

  11. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–10.

    Article  CAS  Google Scholar 

  12. Cheng G, Liu F, Asai T, Lai F, Man N, Xu H, et al. Loss of p300 accelerates MDS-associated leukemogenesis. Leukemia. 2017;31:1382–90. 2017/06/01

    Article  CAS  Google Scholar 

  13. Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, et al. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer Res. 2015;75:5106–19.

    Article  CAS  Google Scholar 

  14. Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, et al. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Adv. 2020;4:4124–35.

    Article  CAS  Google Scholar 

  15. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, et al. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS ONE. 2013;8:e55481.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank The BEAT-AML Master trial, TCGA, and The German-Austrian study group for sharing clinical and genomic data of patients. This work was supported by the Henry and Marilyn Taub Foundation, grants R01HL118281, R01HL123904, R01HL132071, R35HL135795 (all to JPM).

Author information

Authors and Affiliations

Authors

Contributions

SK conceived the study, analyzed the data, and wrote the paper. CMK, WW, SH, and MM performed the genomic sequencing and analyzed genomic data. VA collected clinical information and analyzed whole genome sequencing data. YN, HA, CG, and TH provided patient samples and clinical information. HJR reviewed hematopathology. SP and VV contributed to data analysis, interpretation of the results, wrote and critically reviewed the manuscript. YS and TH contributed to interpretation of the results and critically reviewed the manuscript. JPM conceived the study, designed the experiments, contributed to data analysis, interpretation of the results, and wrote the manuscript. All authors discussed the results and revised the manuscript.

Corresponding author

Correspondence to Jaroslaw P. Maciejewski.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kongkiatkamon, S., Pagliuca, S., Adema, V. et al. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia 36, 1185–1188 (2022). https://doi.org/10.1038/s41375-021-01479-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-021-01479-9

This article is cited by

Search

Quick links